Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID‐19
Top Cited Papers
Open Access
- 11 February 2021
- journal article
- research article
- Published by Wiley in Anaesthesia
- Vol. 76 (5), 608-616
- https://doi.org/10.1111/anae.15442
Abstract
National (and global) vaccination provides an opportunity to control the COVID‐19 pandemic, which disease suppression by societal lockdown and individual behavioural changes will not. We modelled how vaccination through the UK’s vaccine priority groups impacts deaths, hospital and ICU admissions from COVID‐19. We used the UK COVID‐19 vaccines delivery plan and publicly available data to estimate UK population by age group and vaccination priority group, including frontline health and social care workers and individuals deemed ‘extreme clinical vulnerable’ or ‘high risk’. Using published data on numbers and distributions of COVID‐19‐related hospital and ICU admissions and deaths, we modelled the impact of vaccination by age group. We then modified the model to account for hospital and ICU admission, and death among health and social care workers and the population with extreme clinical vulnerability and high risk. Our model closely matches the government’s estimates for mortality after vaccination of priority groups 1–4 and groups 1–9. The model shows vaccination will have a much slower impact on hospital and ICU admissions than on deaths. The early prioritisation of healthcare staff and clinically vulnerable patients increases the impact of vaccination on admissions and also protects the healthcare service. An inflection point, when 50% of the adult population has been vaccinated – with deaths reduced by 95% and hospital admissions by 80% – may be a useful point for re‐evaluating vaccine prioritisation. Our model suggests substantial reductions in hospital and ICU admissions will not occur until late March and into April 2021.This publication has 11 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Occupational COVID‐19 risk for anaesthesia and intensive care staff – low‐risk specialties in a high‐risk settingAnaesthesia, 2020
- Oxford–AstraZeneca COVID-19 vaccine efficacyThe Lancet, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort studyBMJ, 2020
- Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort studyBMJ, 2020
- Use of “normal” risk to improve understanding of dangers of covid-19BMJ, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyBMJ, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020